budesonide / Generic mfg. - LARVOL DELTA

Identification and validation of small molecules with mucin-selective regiospecific binding in the gastrointestinal tract. (PubMed, Biomaterials) - "Additionally, we observe up to a 9-fold increase in budesonide concentration in the small intestine and a 25-fold increase in tetracycline concentration in the stomach. These results show that we have developed a versatile platform capable of sequestering a variety of drugs in certain GI tract organs."

Journal • Gastrointestinal Disorder

CD09 Complexities of contact dermatitis: lessons from a case of concomitant budesonide and propylene glycol sensitivity. (PubMed, Br J Dermatol) - "Positive reactions on day 4 included propylene glycol 20%, colophony 20%, jasmine absolute Egyptian, tixocortol-21-pivalate 1% in petrolatum, budesonide 0.01% in petrolatum and mometasone furoate ointment...Safe alternatives were recommended, while propylene glycol-containing products such as Dermovate, Metosyn and Synalar were to be avoided...Contact Dermatitis 2019; 81: 280-7). Vigilant allergen avoidance, individualized treatment plans and education are paramount for optimal management to prevent exposure to such allergens in future treatments."

Journal • Allergy • Contact Dermatitis • Dermatitis • Dermatology • Immunology

Comparison of Azathioprine-Induced Pancreatitis and Gastrointestinal Intolerance in IBD: Role of Demographics, Clinical Variables, and HLA DQA1/DRB1 Alleles. (PubMed, J Clin Med) - "Regression identified female sex, smoking, alcohol, budesonide, and HLA-DQA1/DRB1 positivity (OR 3.01, 95% CI 1.004-9.058; p = 0.049) as independent risk factors for AZA-AP. GI-INT typically develops within hours to three days of initiation. These findings support AZA-AP and GI-INT as distinct idiosyncratic entities shaped by genetic, metabolic, and sensitivity factors."

Journal • Addiction (Opioid and Alcohol) • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Pancreatitis • HLA-DQA1 • HLA-DRB1

Inhaled Corticosteroid Use and Risk of Haemophilus influenzae Isolation in Patients with Bronchiectasis: A Retrospective Cohort Study. (PubMed, J Clin Med) - "ICS use was standardized in budesonide equivalent doses and categorized in tertiles: low (<210 μg/day), moderate (211-625 μg/day), and high (≥626 μg/day) based on cumulative budesonide equivalent doses redeemed in the 12 months before cohort entry... High-dose ICS use in patients with bronchiectasis was associated with an increased risk of acquiring H. influenzae in the lower respiratory tract. Hence, patients with bronchiectasis should be cautiously prescribed high-dose ICS."

Journal • Retrospective data • Bronchiectasis • Genetic Disorders • Immunology • Infectious Disease • Influenza • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases

CD74-Targeting Antibody-Drug Conjugate Enhances Immunosuppression of Glucocorticoid in Systemic Lupus Erythematosus. (PubMed, Int J Mol Sci) - "To overcome this bottleneck, we developed a CD74-directed antibody-drug conjugate (Bud-ADC) to deliver budesonide, a potent GC drug, selectively to target CD74-expressing immune cells (e.g., B cells, dendritic cells), which play an important role in SLE pathogenesis...This study establishes CD74-targeted ADC as a novel strategy to enhance GC efficacy in SLE, aiming at minimizing off-target toxicity while maintaining broad immunosuppressive activity. The translatable design supports further preclinical and clinical development for autoimmune diseases."

Journal • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • CD74

Case Report: Maximizing the anti-proteinuric response: a multicenter real-world sparsentan case series in IgA disorders. (PubMed, Front Nephrol) - "We present a case series featuring seven patients - five diagnosed with IgAN and two with IgA vasculitis (IgAV) - with severe proteinuria who were treated with Sparsentan, sometimes in combination with other medications such as targeted-release formulation (TRF) budesonide, sodium-glucose cotransporter-2 (SGLT2) inhibitors, or mycophenolate. Sparsentan was well-tolerated overall, with no significant hyperkalemia or hepatotoxicity reported in this group. These cases emphasize the real-world experience, promising efficacy and safety of Sparsentan in reducing proteinuria in patients with IgA-mediated glomerular disorders, including its application in combination therapies and patients with concurrent or prior immunosuppression."

Journal • Real-world evidence • Chronic Kidney Disease • Glomerulonephritis • IgA Nephropathy • Lupus Nephritis • Nephrology • Renal Disease • Vasculitis

A systematic review of therapeutic options for lymphocytic esophagitis. (PubMed, Dis Esophagus) - "For patients with LyE, topical steroids seem to provide greater symptomatic and histologic benefit compared to PPIs, although recurrence is more common. For patients not already on acid suppression therapy, PPIs may still be a reasonable first-line option, especially when prioritizing safety. Further prospective studies are needed to formally assess the comparative safety and efficacy of the various treatment modalities, including novel immunosuppressive therapies."

Journal • Review • Gastrointestinal Disorder

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant (clinicaltrials.gov) - P2 | N=120 | Suspended | Sponsor: University of Utah | Recruiting ➔ Suspended | Trial primary completion date: Jan 2026 ➔ May 2026

Trial primary completion date • Trial suspension • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • Plasma Cell Leukemia • Transplantation • CD34

Reply: Iatrogenic breaching of the junctional zone: the unintended path to placenta accreta spectrum? (PubMed, Facts Views Vis Obgyn) - No abstract available

Journal • Gynecology

Sclerosing Mesenteritis: A Diagnostic Challenge Between Benignity and Malignancy. (PubMed, Cureus) - "For managing symptoms, a three-month course of oral budesonide, agents such as polyethylene glycol, and a dietary plan were provided...Sclerosing mesenteritis is a challenging diagnosis, associated with several benign and malignant etiologies. In this case, the symptoms may result from mass effect or mask another pathology, but the extensive study conducted was insufficient to allow a definitive diagnosis."

Journal • Fibrosis • Immunology • Oncology • Pain

Risk Factors and Management of Incomplete Microscopic Colitis: A Systematic Review and Meta-Analysis. (PubMed, Inflamm Bowel Dis) - "Patients with MCi share similar characteristics with full MC including demographics, risk factors, and response to therapy, indicating that the histologic criteria for MC should potentially be broadened."

Journal • Retrospective data • Gastroenterology • Gastrointestinal Disorder • Immunology

Intranasal corticosteroids: a promising new approach for adults with chronic idiopathic urticaria linked to aeroallergens - a double-blind randomized clinical trial. (PubMed, Skin Health Dis) - "In this double-blind placebo-controlled trial, 69 adults with CIU sensitized to aeroallergens received budesonide 32 µg per actuation, 2 sprays per nostril twice daily or identical placebo for 6 months while maintained on a stable single-agent nonsedating H1 antihistamine...Intranasal corticosteroids were effective in reducing urticaria symptoms but did not offer significant benefits over placebo with regard to overall quality of life. The results highlight the complexity of CIU management and suggest a potential placebo effect."

Clinical • Journal • Allergic Rhinitis • Cardiovascular • Chronic Spontaneous Urticaria • Dermatology • Immunology • Inflammation • Urticaria

Economic Burden of Microscopic Colitis in Relation to Disease Activity: A Nationwide Cost-of-illness Study. (PubMed, J Crohns Colitis) - "Compared with the general population, patients with MC had almost twice as high annual mean costs. Excess costs were particularly high in patients with a high disease activity at onset, mainly driven by work loss."

HEOR • Journal • Gastroenterology • Gastrointestinal Disorder • Immunology

Treatment of Recurrent IgA Nephropathy After Kidney Transplantation: Case Report and Comprehensive Literature Review. (PubMed, Clin Case Rep) - "Recurrent IgA nephropathy after kidney transplantation remains a major cause of graft dysfunction. This case highlights successful management with targeted-release budesonide combined with sparsentan, underscoring the importance of early recognition and the promise of emerging therapies to preserve long-term allograft function."

Journal • Glomerulonephritis • IgA Nephropathy • Renal Disease • Transplantation

Comprehensive assessment beyond eosinophils in eosinophilic esophagitis: an updated network meta-analysis. (PubMed, BMC Gastroenterol) - "This study suggests that Dupilumab 300mg qw might be the best performing agent for induction of clinical improvement (the primary endpoint) and BODT might be the most efficacious agents for histological and endoscopic improvement (the secondary endpoint). This could provide evidence for clinical therapy strategy for EoE patients."

Journal • Retrospective data • Review • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: University of Utah | Trial primary completion date: Sep 2025 ➔ Jan 2026

Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation • CD34

Randomised trial of Budesonide Orodispersible tablet (BOT) at 2mg orally once daily compared to 1mg orally once daily in patients with Eosinophilic oesophagitis (EoE) who initially respond to Budesonide 1mg orally twice daily. (ANZCTR) - P4 | N=72 | Not yet recruiting | Sponsor: Northern Adelaide Local Health Network

New P4 trial • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology

Matching-adjusted indirect comparison of kidney function in patients with immunoglobulin A nephropathy treated with nefecon or sparsentan. (PubMed, J Comp Eff Res) - P3 | "Aim: We compared the effects of nefecon, an oral targeted-release budesonide formulation, and sparsentan, an oral, dual endothelin-angiotensin receptor antagonist, on estimated glomerular filtration rate (eGFR) in patients with immunoglobulin A nephropathy, a leading cause of chronic kidney disease. Materials & We conducted an anchored matching-adjusted indirect comparison (MAIC) using patient-level data from NefIgArd (NCT03643965; n = 364), a randomized (1:1) trial of nefecon plus optimized renin-angiotensin system inhibitor (RASi) therapy versus placebo plus RASi; and aggregate data from PROTECT (NCT03762850; n = 404), a randomized (1:1) trial of sparsentan versus irbesartan, an angiotensin receptor blocker...Sensitivity analysis results were consistent with the main findings. In patients with immunoglobulin A nephropathy, nefecon plus optimized RASi may preserve kidney function to a greater extent than sparsentan."

Journal • Chronic Kidney Disease • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease

Characterization of pediatric eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis in a nationwide cohort. (PubMed, J Pediatr Gastroenterol Nutr) - "Pediatric non-EoE EGIDs present with heterogeneous symptoms and variable tract involvement. Younger children show distinct phenotypes. Laboratory findings are nonspecific and have limited diagnostic utility. Treatment remains challenging, with suboptimal response rates. These findings underscore the need for prospective studies."

Clinical • Journal • Eosinophilia • Eosinophilic Esophagitis • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Immunology • Inflammation • Pain • Pediatrics

Palbociclib-Induced Apoptotic Colopathy: A Case Report and Review of the Literature. (PubMed, Eur J Case Rep Intern Med) - "Although diarrhoea is a common side effect, palbociclib can, in rare cases, cause severe colitis with deep ulcers at video colonoscopy; internists should be aware of this underrecognized adverse effect.Histologic findings of increased epithelial apoptosis can support the diagnosis of drug-induced apoptotic colopathy.Oral budesonide, commonly used in microscopic colitis, may be an effective treatment for CDK4/6 inhibitor-induced colitis, offering a well-tolerated therapeutic option."

Journal • Breast Cancer • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Immunology • Oncology • Solid Tumor • HER-2

A liquid biopsy-RNAseq method for monitoring the expression of genes involved in drug disposition: Proof-of-concept application to cholestatic liver disease. (PubMed, J Pharm Biomed Anal) - "The model reflected exposure to budesonide and cyclosporine consistent with early-stage disease. The model also reflected increased total serum bilirubin, likely due to dysregulation of hepatobiliary transport."

Journal • Liquid biopsy • Cholestasis • Hepatology

A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission (clinicaltrials.gov) - P2 | N=54 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology

When IgA Strikes Twice: The Battle Beyond Transplant (KIDNEY WEEK 2025) - "Initial management included losartan 100 mg daily, which led to a modest improvement in proteinuria (1.2 g/g) and creatinine (1.7 mg/dL)...Targeted-release budesonide (TRF-budesonide; Tarpeyo) was initiated at 16mg/d in addition to standard triple immunosuppression and resulted in a significant reduction in proteinuria (0.9g/g), resolution of hematuria, and stabilization of allograft function over 4 months (Figure)...Its targeted mechanism at the gut mucosal immunity provides the necessary immunosuppressive effect while avoiding additional systemic immunosuppression in this high-risk population. We encourage clinical trials to establish long-term efficacy and safety in the transplant population."

Cardiovascular • Diabetes • Diabetic Nephropathy • Glomerulonephritis • Hypertension • IgA Nephropathy • Metabolic Disorders • Nephrology • Transplantation

Creation and Initial Demographics of the PERFORM Patient Registry: Novel Real-World Registry of Patients Treated for IgAN in the United States (KIDNEY WEEK 2025) - "To address this need, the PERFORM Patient Registry TM (PPR) has been created to assess longitudinal disease characteristics, healthcare utilization, clinical management, and treatment utilization patterns of patients treated with delayed release budesonide (Tarpeyo®) for IgAN in the United States (US). Conclusion While enrollment is ongoing, the current PPR population contains a varied cohort of patients treated with Tarpeyo® for IgAN. This registry will allow for further understanding of IgAN management and outcomes for patients treated with Tarpeyo® for IgAN."

Clinical • Real-world • Real-world evidence • Glomerulonephritis • IgA Nephropathy • Pediatrics • Renal Disease

Therapies for IgAN in the Cure Glomerulonephropathy Network (CureGN) (KIDNEY WEEK 2025) - "Few participants (n=5) received newer IgAN therapies (eg, sparsentan, targeted delayed-release budesonide)...Conclusion The impact of traditional IST on long term kidney function requires further exploration. Despite availability of novel IgAN therapies, conservative management (RAS inhibition, SGLT2i) and traditional IST remain most used."

Glomerulonephritis • IgA Nephropathy • Renal Disease